BEAM FINANCIAL STATEMENTS

Beam Therapeutics Inc — balance sheet, income statement and cash flow trends

BEAMBeam Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue164 M $+158.0%

Gross Profit-53.2 M $—

Operating Income-371.6 M $—

EBITDA-32 M $—

Net Income-65 M $—

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
BEAM	158.0%	-32.4%	-19.5%	-39.7%
TLX	56.3%	50.8%	3.0%	-0.9%
MSB	410.4%	-32.0%	-76.6%	-115.3%
CSL	4.8%	48.6%	32.8%	9.2%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
BEAM	158.0%	-32.4%	-19.5%	-39.7%
RCUS	67.4%	97.0%	-139.8%	-156.4%
DYN	-100.0%	—	—	—
RARE	13.3%	83.6%	-75.2%	-91.0%
RLAY	39.0%	-546.2%	-2,560.7%	-2,554.1%
IDYA	3,118.1%	29.7%	-60.1%	-62.2%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity1.2 B $79%
Current Liabilities74.6 M $5%
Long-term Liabilities241.8 M $16%

Key Figures

YoY change

Total Assets1.5 B $+0.9%

Total Liabilities316.4 M $-8.0%

Total Equity1.2 B $+3.7%

Cash & ST Investments1.2 B $-0.7%

Total Debt250.8 M $+58.6%

Net Debt-37.5 M $—

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
BEAM	16.99	21.5%	30.00	78.6%
TLX	1.43	112.3%	13.13	35.1%
MSB	—	—	—	—
CSL	2.57	67.4%	2.22	49.2%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
BEAM	16.99	21.5%	30.00	78.6%
RCUS	4.04	21.6%	2.15	52.6%
DYN	19.92	2.2%	2.20	80.1%
RARE	2.02	-508.5%	-1.56	-18.2%
RLAY	22.13	4.9%	2.23	91.8%
IDYA	10.74	3.1%	4.74	91.0%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-369.7 M $—

Capital Expenditures14.1 M $+47.4%

Free Cash Flow-383.8 M $—

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
BEAM	-225.4%	-234.0%	8.6%	568.5%
TLX	-2.2%	-6.3%	4.1%	243.1%
MSB	-87.7%	-90.0%	2.3%	76.1%
CSL	24.0%	20.3%	3.7%	261.5%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
BEAM	-225.4%	-234.0%	8.6%	568.5%
RCUS	-206.8%	-207.2%	0.4%	132.2%
DYN	—	—	—	97.9%
RARE	-74.2%	-72.8%	2.4%	81.5%
RLAY	-1,998.3%	-1,998.5%	0.3%	78.2%
IDYA	-38.1%	-39.0%	0.9%	61.3%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on BEAM

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.